Published in Dig Dis Sci on January 29, 2014
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut (2002) 1.68
Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med (1967) 1.51
Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost (2007) 1.38
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost (2006) 1.37
Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol (2002) 1.30
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood (2009) 1.13
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost (2011) 1.01
Histopathology of portal hypertension: a practical guideline. Histopathology (2003) 0.98
Hepatoportal sclerosis. Semin Liver Dis (1995) 0.96
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. AJR Am J Roentgenol (2015) 1.99
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice. Hepatology (2014) 1.62
Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant (2003) 1.60
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood (2011) 1.50
Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park) (2013) 1.49
Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood (2009) 1.48
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood (2006) 1.42
Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology (2012) 1.40
Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol (2014) 1.40
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res (2012) 1.35
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood (2012) 1.26
Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology (2012) 1.24
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood (2013) 1.19
Surgical management of complications after hearing aid fitting. Laryngoscope (2004) 1.19
Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood (2006) 1.17
Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. Br J Haematol (2012) 1.14
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood (2009) 1.13
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol (2011) 1.12
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis (2007) 1.12
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol (2006) 1.12
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol (2010) 1.12
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood (2013) 1.11
Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol (2008) 1.10
Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest (2014) 1.09
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res (2007) 1.04
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res (2010) 1.03
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol (2008) 1.02
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology (2012) 1.01
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci (2012) 0.98
Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol (2006) 0.97
Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. Cancer Epidemiol Biomarkers Prev (2009) 0.96
Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol (2012) 0.96
Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol (2002) 0.95
Revision cochlear implant surgery in patients with suspected soft failures. Otol Neurotol (2010) 0.95
Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest (2004) 0.94
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol (2013) 0.94
Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol (2005) 0.93
The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood (2011) 0.92
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res (2009) 0.92
A multidisciplinary investigation of a polycythemia vera cancer cluster of unknown origin. Int J Environ Res Public Health (2010) 0.91
Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood (2011) 0.91
Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91
Advances in myelofibrosis: a clinical case approach. Haematologica (2013) 0.91
Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl (2006) 0.90
Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl (2009) 0.90
Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res (2010) 0.90
Cytokines for the treatment of thrombocytopenia. Semin Hematol (2007) 0.90
Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg (2010) 0.88
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol (2012) 0.88
Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis (2005) 0.87
Fulminant hepatic failure attributed to ackee fruit ingestion in a patient with sickle cell trait. Case Rep Transplant (2012) 0.87
Endothelial precursor cells in the peripheral blood of pregnant women. J Soc Gynecol Investig (2002) 0.87
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics (2011) 0.87
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol (2012) 0.87
Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. Liver Transpl (2014) 0.87
Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol (2011) 0.87
Idiopathic myelofibrosis. Semin Hematol (2005) 0.87
Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl (2006) 0.87
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood (2004) 0.86
Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol (2007) 0.86
WEO Newsletter. Dig Endosc (2015) 0.85
Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant (2012) 0.84
Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood (2011) 0.84
Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci (2013) 0.84
Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol (2009) 0.84
Right hepatectomy for living donation: role of remnant liver volume in predicting hepatic dysfunction and complications. Surgery (2013) 0.83
BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood (2013) 0.83
Diagnostic and prognostic utility of measuring tumor necrosis factor in the peripheral circulation of patients with immune-mediated sensorineural hearing loss. Arch Otolaryngol Head Neck Surg (2012) 0.83
Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates. Biol Blood Marrow Transplant (2004) 0.83
Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation (2005) 0.83
Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease. J Crohns Colitis (2012) 0.83